€1.46
1.11% today
Amsterdam, Aug 25, 05:22 pm CET
ISIN
NL00150002Q7
Symbol
VVY

Vivoryon Therapeutics Stock price

€1.46
+0.02 1.39% 1M
-0.56 27.54% 6M
-0.53 26.63% YTD
-0.75 33.94% 1Y
-6.44 81.52% 3Y
-3.49 70.51% 5Y
-20.94 93.48% 10Y
-18.54 92.70% 20Y
Amsterdam, Closing price Mon, Aug 25 2025
+0.02 1.11%
ISIN
NL00150002Q7
Symbol
VVY
Industry

Key metrics

Basic
Market capitalization
€37.7m
Enterprise Value
€28.4m
Net debt
positive
Cash
€9.4m
Shares outstanding
26.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.8
Financial Health
Equity Ratio
69.8%
Return on Equity
-261.0%
ROCE
-212.2%
ROIC
-2,525.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
€0.0 | €0.0
EBITDA
€-20.8m | €-14.1m
EBIT
€-21.0m | €-15.4m
Net Income
€-20.6m | €-11.5m
Free Cash Flow
€-19.2m
Growth (TTM | estimate)
Revenue
100.0% | -
EBITDA
27.4% | 32.3%
EBIT
27.3% | 26.5%
Net Income
27.4% | 44.3%
Free Cash Flow
13.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
€-0.8
FCF per Share
€-0.7
Short interest
-
Employees
14
Rev per Employee
€0.0
Show more

Is Vivoryon Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Vivoryon Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Vivoryon Therapeutics forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Vivoryon Therapeutics forecast:

Buy
75%
Hold
25%

Financial data from Vivoryon Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.90 6.90
20% 20%
-
- Research and Development Expense 14 14
20% 20%
-
-21 -21
27% 27%
-
- Depreciation and Amortization 0.15 0.15
12% 12%
-
EBIT (Operating Income) EBIT -21 -21
27% 27%
-
Net Profit -21 -21
27% 27%
-

In millions EUR.

Don't miss a Thing! We will send you all news about Vivoryon Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Vivoryon Therapeutics NV is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its product pipeline includes PQ912, PBD-C06, and PQ1565. The company was founded by Hans-Ulrich Demuth and Konrad Glund on July 25, 1997 and is headquartered in Halle, Germany.

Head office Netherlands
CEO Frank Weber
Employees 14
Founded 1997
Website www.vivoryon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today